COMMENTARY
The long term prognosis for patients with decompensated cirrhosis is poor. For patients with chronic HBV, the therapeutic options include liver transplantation, which is limited by the current paucity of organs; low dose interferon, which is not very effective for Child's class B/C disease (1) and may cause further deterioration (2); or antiviral agents. Lamivudine is a well tolerated antiviral agent with efficacy in suppressing HBV replication (3) . In the present study, lamivudine demonstrated efficacy in improving the clinical situation of patients with decompensated cirrhosis. These encouraging findings are tempered by the fact that 34% either died of liver disease or underwent transplantation within the first six months of the study. Furthermore, another three patients died of liver disease or required transplantation after six months. Clearly lamivudine can help some patients but does not replace timely referral for transplantation.
Another concern with the long term use of lamivudine is the development of YMDD motif lamivudine-resistant HBV strains. The Asian study group has reported the emergence of these mutants in approximately 40% after two years of lamivudine use (3) . Although the YMDD mutant is considered less virulent than the wild-type strain (4), progressive liver disease can still occur (5) , and active viremia with HBV remains a contraindication for transplantation in
